Corbus Pharmaceuticals Expands Oncology Pipeline; Enters Exclusive Licensing Agreement

Precision oncology company, Corbus Pharmaceuticals (Nasdaq: CRBP), will commercialize its clinical stage antibody drug, CRB-701, with CSPC Megalith Biopharmaceutical.

CRB-701 is a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload. CSPC is currently investigating CRB-701 in a Phase 1 clinical trial to treat advanced solid tumors in China.

Highlights

• The exclusive agreement covers commercialization rights to CRB-701 in the US, Canada, the European Union, the United Kingdom, and Australia.
• As part of the deal, CSPC will receive an upfront payment of $7.5 million.
• CSPC will also be eligible to receive royalties on net sales and up to $130 million in potential development and regulatory milestone payments and $555 million in potential commercial milestone payments.
• Corbus has received FDA clearance to evaluate CRB-701 as an Investigational New Drug (IND) and anticipates commencing a Phase 1 clinical trial in CRB-701 in the US in 2024.

Corbus’ current pipeline includes CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and CRB-701, which is designed to act on a broad range of Nectin-4 expressing tumors.